Valrocemide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329480

CAS#: 92262-58-3

Description: Valrocemide, also known as TV-1901, is an antiepileptic drug (AED). Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy.


Price and Availability

Size
Price

100mg
USD 650
1g
USD 2250
Size
Price

200mg
USD 950
2g
USD 3850
Size
Price

500mg
USD 1650
5g
USD 5750

Valrocemide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329480
Name: Valrocemide
CAS#: 92262-58-3
Chemical Formula: C10H20N2O2
Exact Mass: 200.1525
Molecular Weight: 200.282
Elemental Analysis: C, 59.97; H, 10.07; N, 13.99; O, 15.98


Synonym: Valrocemide; TV-1901; TV 1901; TV1901; SPD-493; TVP-1901; SPD493; TVP1901; SPD 493; TVP 1901;. N-Valproyl glycinamide.

IUPAC/Chemical Name: N-(2-amino-2-oxoethyl)-2-propylpentanamide

InChi Key: RALGCAOVRLYSMA-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14)

SMILES Code: CCCC(CCC)C(NCC(N)=O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Hovinga CA. Valrocemide (Teva/Acorda). Curr Opin Investig Drugs. 2004 Jan;5(1):101-6. Review. PubMed PMID: 14983982.

2: Isoherranen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 2001 Jul;42(7):831-6. PubMed PMID: 11488880.

3: Shaltiel G, Mark S, Kofman O, Belmaker RH, Agam G. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep. 2007 Jul-Aug;59(4):402-7. Erratum in: Pharmacol Rep. 2008 Mar-Apr;60(2):292. Galit, Shaltiel [corrected to Shaltiel, Galit]; Shirley, Mark [corrected to Mark, Shirley]; Ora, Kofman [corrected to Kofman, Ora]; Galila, Agam [corrected to Agam, Galila]. PubMed PMID: 17901568.

4: Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, Jargiełło M, Czuczwar SJ. New generation of valproic acid. Pol J Pharmacol. 2004 May-Jun;56(3):283-8. Review. PubMed PMID: 15215557.

5: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004 Sep-Oct;61(1-3):1-48. PubMed PMID: 15570674.

6: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002 Sep;51(1-2):31-71. PubMed PMID: 12350382.

7: Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009 Mar-Apr;61(2):197-216. Review. PubMed PMID: 19443931.

8: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. doi: 10.1016/j.eplepsyres.2008.09.005. PubMed PMID: 19008076.

9: Hadad S, Bialer M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm Drug Dispos. 1997 Oct;18(7):557-66. PubMed PMID: 9330777.

10: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007 Jan;73(1):1-52. PubMed PMID: 17158031.

11: Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. Review. PubMed PMID: 16732716.

12: Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006 Jun;69(3):273-94. Review. PubMed PMID: 16621450; PubMed Central PMCID: PMC1562526.

13: Spiegelstein O, Yagen B, Bialer M. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia. 1999 May;40(5):545-52. PubMed PMID: 10386522.

14: Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release. 1999 Nov 1;62(1-2):187-92. PubMed PMID: 10518650.

15: Hovinga CA. Novel anticonvulsant medications in development. Expert Opin Investig Drugs. 2002 Oct;11(10):1387-406. Review. PubMed PMID: 12387702.

16: Spiegelstein O, Bialer M, Yagen B. Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Sep 26;698(1-2):195-200. PubMed PMID: 9367208.

17: Nicolson A, Leach JP. Future prospects for the drug treatment of epilepsy. CNS Drugs. 2001;15(12):955-68. Review. PubMed PMID: 11735615.

18: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001 Jan;43(1):11-58. PubMed PMID: 11137386.